763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP

Wellington Management Group LLP purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 763,943 shares of the company's stock, valued at approximately $19,458,000. Wellington Management Group LLP owned about 1.48% of Bicara Therapeutics as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Cinctive Capital Management LP purchased a new stake in Bicara Therapeutics in the 3rd quarter worth about $229,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Bicara Therapeutics in the third quarter worth about $462,000. Soros Fund Management LLC bought a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $509,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at approximately $582,000. Finally, Walleye Capital LLC bought a new position in Bicara Therapeutics in the 3rd quarter worth approximately $809,000.

Bicara Therapeutics Stock Down 3.0 %

Bicara Therapeutics stock traded down $0.55 during trading hours on Friday, reaching $17.50. The stock had a trading volume of 312,508 shares, compared to its average volume of 355,107. Bicara Therapeutics Inc. has a 52 week low of $17.30 and a 52 week high of $28.09. The company's fifty day simple moving average is $21.21.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). As a group, sell-side analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCAX has been the topic of a number of analyst reports. Cantor Fitzgerald began coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set an "overweight" rating on the stock. Stifel Nicolaus began coverage on Bicara Therapeutics in a research note on Tuesday, October 8th. They set a "buy" rating and a $47.00 price objective for the company. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price on the stock. TD Cowen started coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a "buy" rating for the company. Finally, RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $43.00.

Insiders Place Their Bets

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. bought 1,833,000 shares of the firm's stock in a transaction on Monday, September 16th. The stock was acquired at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the purchase, the director now owns 4,303,418 shares of the company's stock, valued at approximately $77,461,524. This trade represents a 74.20 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn purchased 70,000 shares of the company's stock in a transaction dated Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the completion of the transaction, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This represents a 8.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.